Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 348

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 348
---
                      3 |     |           3 |
| At December 31, 2023                    |     |                                    13,378 |     |          2,291 |     |                    107 |     |      15,776 |
| Amortisation charge for the period      |     |                                         – |     |              – |     |                      1 |     |           1 |
| At June 30, 2024 (unaudited)            |     |                                    13,378 |     |          2,291 |     |                    108 |     |      15,777 |
| Net book value                          |     |                                           |     |                |     |                        |     |             |
| At June 30, 2024 (unaudited)            |     |                                     6,006 |     |              – |     |                      2 |     |       6,008 |
| At December 31,2023                     |     |                                     2,938 |     |              – |     |                      3 |     |       2,941 |

The individual intangible assets which
are material to the financial statements are as follows:

| Schedule of individual intangible assets |     | Carrying amount |             June 30, 
 2024 unaudited £’000 |     |       December 
 31, 2023 £’000 |     | Remaining amortisation 
 period                 
 June 30,               
 2024 unaudited £’000   |     | December       
 31, 2023 £’000 |
|:-----------------------------------------|:----|:----------------|---------------------:|:----|---------------:|:----|:-----------------------|:----|:---------------|
| MTX228 tolimidone acquired IPRD*         |     |                 |                2,938 |     |          2,938 |     | n/a                    |     | n/a            |
| MTX230 eRapa acquired IPRD*              |     |                 |                3,068 |     |              – |     | n/a                    |     | n/a            |

*asset is not yet in
use and has not started amortising

On April 25, 2024 the
Company entered into a License and Collaboration Agreement (LCA) with Rapamycin Holdings, Inc. (d/b/a Emtora Biosciences), relating to
the license